The effect of selenium on cancer related-fatigue

Phase 3

Recruiting

• Conditions: Cancer-related fatigue.; Neoplasm-related fatigue; R53.0

• Registration Number: IRCT20210825052293N1
• Lead Sponsor: Esfahan University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 1 November 2021

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 70

Inclusion Criteria

30 to 60 years of age
To be able to read and write
Definitive diagnosis of cancer which requires chemotherapy and has been confirmed with pathology findings and authenticated by an oncology subspecialist
Not having another treatment regimen that has healing effect on fatigue
To have cancer-related fatigue and score of 40 and above in fatigue questionnaire
To tolerate oral medication
To cooperate and agree with the study

Exclusion Criteria

Patients with known depression undergoing treatment
Having anemia
Having a disease that prevents patient from continuing participation in study
When more than 20% of the questionnaire has not been completed
Pregnancy and lactation
Renal failure
Taking medications such as baloxavir, marboxil, deferiprone, cabotegravir, bisphosphonate derivatives, bictegravir, dolutegravir, eltrombopag, trientine, raltegravir, penicillamine, elvitegravir
Known allergy to selenium
Hypothyroidism
Skin cancer and individulas at high risk for developing squamous cell carcinoma

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Cancer-related fatigue. Timepoint: Zero, 3 weeks, 6 weeks. Method of measurement: Multivariable questionnaire.